Leveraging Ultra-sensitive MRD, RWD & Global Scale to Enable ctDNA-guided Drug Development
Time: 12:00 pm
day: Conference Day 1
Details:
- Natera is a pioneer in molecular disease monitoring, offering a market-leading portfolio of ultra-sensitive assays (down to 1ppm), real-world data, and integrated trial support
- Explore how Natera’s commercial footprint, global trial infrastructure, and scientific expertise enable scalable execution of ctDNA-guided trials
- Delve into Natera’s expanding portfolio, recent clinical evidence, and strategic vision for advancing drug development
